Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 11, 2022
Product Development
Oct. 10 Quick Takes: WuXi Biologics clears one unit from U.S. watch list
Plus liver disease RNA company Ochre raises $30M, and updates from Supernus, RadioMedix, Hua, JW and scPharmaceuticals
BioCentury | Mar 5, 2022
Management Tracks
Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
BioCentury | Sep 27, 2021
Product Development
Hua’s diabetes therapy may be first to show clinical remission
Early stage Type II diabetes patients maintain HbA1c target after use of GCK activator dorzagliatin
BioCentury | Apr 27, 2021
Regulation
April 26 Quick Takes: U.S. to release 60M doses of AZ vaccine to other countries; plus IP pact, ADC, GSK, uniQure, Hua, Reata, Axsome and more
The U.S. will release 60 million doses of the COVID-19 vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford to other countries as they become available, according to Andy
BioCentury | Aug 17, 2020
Deals
China’s Hua looks to Bayer to commercialize lead diabetes therapy on its own turf
China’s top diabetes sales force to sell first-in-class GCK activator dorzagliatin
BioCentury | Jul 2, 2020
Product Development
July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein
BioCentury | Jun 19, 2020
Product Development
Hua shows sustained benefit in diabetics with glucokinase activator
BioCentury | May 14, 2020
Emerging Company Profile
Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity
Kriya plans to extend gene therapies to prevalent, chronic diseases
BioCentury | Feb 11, 2020
Product Development
vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle
BioCentury | Nov 13, 2019
Clinical News
Hua Phase III diabetes data make good on glucokinase but disappoint investors
Hua’s glucokinase activator notches a Phase III win for the long-pursued target
Items per page:
1 - 10 of 63